These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 7560253)
21. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Michaud V; Mouksassi MS; Labbé L; Bélanger PM; Ferron LA; Gilbert M; Grech-Bélanger O; Turgeon J Ther Drug Monit; 2006 Dec; 28(6):779-83. PubMed ID: 17164694 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group. Zoble RG; Kirsten EB; Brewington J Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109 [TBL] [Abstract][Full Text] [Related]
23. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. Jazwinska-Tarnawska E; Orzechowska-Juzwenko K; Niewinski P; Rzemislawska Z; Loboz-Grudzien K; Dmochowska-Perz M; Slawin J Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772 [TBL] [Abstract][Full Text] [Related]
24. Assessment of the antiarrhythmic profile of the new class I agent diprafenone. Gülker H; Thale J; Olbing B; Heuer H; Frenking B; Bender F Arzneimittelforschung; 1985; 35(9):1387-93. PubMed ID: 4084340 [TBL] [Abstract][Full Text] [Related]
25. Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses. Frabetti L; Marchesini B; Capucci A; Cavallini C; Gubelli S; Ambrosioni E; Magnani B Eur J Clin Pharmacol; 1986; 30(6):665-71. PubMed ID: 2429844 [TBL] [Abstract][Full Text] [Related]
26. On the mechanism of drug-induced blockade of Na+ currents: interaction of antiarrhythmic compounds with DPI-modified single cardiac Na+ channels. Kohlhardt M; Fichtner H; Fröbe U; Herzig JW Circ Res; 1989 May; 64(5):867-81. PubMed ID: 2539922 [TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers. Williams FM; Leeser JE; Rawlins MD Br J Clin Pharmacol; 1986 Sep; 22(3):301-8. PubMed ID: 3768242 [TBL] [Abstract][Full Text] [Related]
29. Interaction between propranolol and propafenone in healthy volunteers. Kowey PR; Kirsten EB; Fu CH; Mason WD J Clin Pharmacol; 1989 Jun; 29(6):512-7. PubMed ID: 2754020 [TBL] [Abstract][Full Text] [Related]
30. LG 6-101 and LG 6-102, two new propafenone-related antiarrhythmic agents with good oral activity in rats. Wascher TC; Dittrich P; Kukovetz WR Naunyn Schmiedebergs Arch Pharmacol; 1992 Apr; 345(4):473-7. PubMed ID: 1620247 [TBL] [Abstract][Full Text] [Related]
31. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. Wójcicki J; Sulzyc-Bielicka V; Kutrzeba J; Gawrońska-Szklarz B; Droździk M; Sterna Z J Clin Pharmacol; 1999 Aug; 39(8):826-33. PubMed ID: 10434235 [TBL] [Abstract][Full Text] [Related]
32. Kinetics and dynamics of sematilide. Shi J; Lasser T; Koziol T; Hinderling PH Ther Drug Monit; 1995 Oct; 17(5):437-44. PubMed ID: 8585104 [TBL] [Abstract][Full Text] [Related]
33. Normal-phase high-performance liquid chromatographic procedure for the determination of diprafenone in plasma. Austin D; Koziol T; Woolf E; Espinosa-Crouch G J Chromatogr; 1990 Apr; 527(1):182-8. PubMed ID: 2365778 [No Abstract] [Full Text] [Related]
34. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535 [TBL] [Abstract][Full Text] [Related]
35. Drug-drug interactions between antiarrhythmic drugs in chick embryos. Yoshiyama Y; Sugiyama T; Kanke M; Tsuchimoto K Biol Pharm Bull; 2004 Jan; 27(1):128-30. PubMed ID: 14709916 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol. Vinceneux P; Canal M; Domart Y; Roux A; Cascio B; Orofiamma B; Larribaud J; Flouvat B; Carbon C Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):153-8. PubMed ID: 2870990 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects. Murdoch DL; Thomson GD; Thompson GG; Murray GD; Brodie MJ; McInnes GT Br J Clin Pharmacol; 1991 Mar; 31(3):323-32. PubMed ID: 2054272 [TBL] [Abstract][Full Text] [Related]